Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated with Tucatinib

What is the Purpose of this Study?

We are doing this study to test a program that is being developed by nurses to help patients with HER2+ metastatic breast cancer manage their treatment with three drugs typically used for this diagnosis: tucatinib, trastuzumab, and capecitabine. The program's goal is to help patients manage symptoms and provide resources to improve their quality of life.

What is the Condition Being Studied?

HER2+ Metastatic Breast Cancer

Who Can Participate in the Study?

Women ages 18+ who:

  • Are diagnosed with HER2+ metastatic breast cancer
  • Are being treated with tucatinib, trastuzumab, and capecitabine

For more information, contact the study team at michael.w.willis@duke.edu.

Age Group
Adults

What is Involved?

If you choose to participate, you will be asked to:

  • Meet with a nurse navigator via Zoom for three sessions, about 40 minutes each, over a period of six weeks
  • Complete three surveys, which take about 30 minutes each to complete, over the 6-week study period
  • Be asked to share your feedback about the program during an interview over Zoom

    • Study Details

    Full Title
    Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated with Tucatinib
    Principal Investigator
    Headshot of Rebecca A Shelby
    Professor in Psychiatry and Behavioral Sciences
    Protocol Number
    IRB: PRO00117920
    NCT: NCT06983691
    Phase
    Phase Pilot
    ClinicalTrials.gov
    Status
    OPEN TO ACCRUAL